[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518745":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":43,"collaborators":19,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":19,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":19,"maxAge":53,"enrollmentInfo":54,"targetDuration":19,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":19,"overallStatus":31,"whyStopped":19,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Hong Kong Children's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","CD62L depleted donor lymphocyte infusion",[13],"Biological: CD62L depleted donor lymphocyte infusion",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Intravenous infusion of CD62L depleted donor lymphocytes",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Daniel Cheuk","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","85235136049","cheukkld@gmail.com",[30],{"facility":5,"status":31,"city":32,"state":19,"zip":19,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Hong Kong","HK",{"type":35,"coordinates":36},"Point",[37,38],114.17469,22.27832,{"lat":38,"lon":37},[41],{"name":22,"role":26,"phone":42,"phoneExt":19,"email":28},"852-35136049",{"type":23,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Cheuk Ka Leung Daniel","Consultant","100518745","phase-2-cd62l-depleted-donor-lymphocyte-infusion-with-t-cell-depleted-haploidentical-hematopoietic-stem-cell-transplantation-100518745",false,"NCT06034535","CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patient who requires allogeneic hematopoietic stem cell transplant, has no human leukocyte antigen (HLA)-matched sibling donor but has an HLA-haploidentical donor.\n* Adequate organ function to tolerate the conditioning chemotherapy and radiotherapy\n* Karnofsky or Lansky performance status score ≥50\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* HIV infection\n* Patients for whom alternative treatment is deemed more appropriate by treating physician\n* Patients who are unlikely to benefit from haploidentical hematopoietic stem cell transplantation, e.g., terminal malignancy with multiorgan failure","ALL","18 Years",{"count":55,"type":56},23,"ESTIMATED","INTERVENTIONAL",[59],"PHASE2","In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with malignant or non-malignant disease in need of HSCT. The investigators shall evaluate the graft failure-free, graft-versus-host disease (GVHD)-free survival at one year, frequency of adverse events and post-transplant complications, and immunoreconstitution.",[62],"Hematopoietic Organs; Disorder","2025-09-08",{"date":65,"type":66},"2025-09-15","ACTUAL",{"date":68,"type":66},"2023-09-01",{"date":70,"type":56},"2026-09",{"name":5,"class":6},1]